Rabbit VX2 lung tumor models can form early nodal metastases

Lung cancer is the leading cause of cancer death globally [1]. Effective animal models play a key part in developing and evaluating new therapeutic approaches. Mouse lung cancer models are reasonable options for evaluating systemic therapy but have limitations for evaluating other modalities, such as novel surgical and endoscopic technologies. Rabbits, by comparison, are better sized for such research. VX2 is a rabbit squamous cell cancer line that has been used to generate rabbit tumor models at a variety of sites, including uterus, tongue, stomach, hypopharynx, breast, rectum, muscle, cheek, liver, and lung; this cell line is well-documented in its ability to generate nodal metastases [2‐11]. However, there is significant variation in the timing of nodal metastases based on VX2 inoculation protocol (e.g., primary inoculation site, cell count of inoculum, media). This is further complicated by heterogeneity in the time from inoculation to sacrifice (ranging from days to months). It is known that VX2 lung tumor models can generate nodal metastases, but this has been largely demonstrated on autopsy after animals died from uncontrolled disease at 26 to around 40 days [12, 13]. Those studies that stratified rabbits by time from inoculation did so for assessing changes on imaging or responses to radiofrequency ablation; the timing of nodal metastasis development was therefore unclear [12, 14]. Considered together, VX2 nodal metastases have not been well-characterized for rabbit lung tumor models. Understanding when VX2 lung tumor models develop metastases and the pattern of spread is critical in informing the use of these models as surrogates for both early-stage and advanced lung cancer patients. Lymph node metastasis is significantly associated with lung cancer prognosis and is a key factor in treatment decision-making [15, 16].

Our group has previously described a peripheral VX2 lung tumor model using bronchoscopic injection [11]. An extracellular matrix (ECM) protein suspension is vital to prevent post-injection leakage, which could otherwise result in unintentionally diffuse disease or expectoration of the inoculum [17]. Compared to previous work characterizing VX2 nodal metastases, the combination of a different inoculation site (lung) and media (ECM suspension), among other differences, may significantly alter the generation of spontaneous VX2 nodal metastases. We sought to determine whether transbronchial VX2 inoculation can generate early nodal metastases (i.e., prior to significant progression of disease) and if so, to characterize the timing and nature of those metastases. We hypothesized that we could identify a time point where the models would have both primary tumors and nodal metastases without development of widely disseminated disease, making them viable models for future study.

Animal use and care was previously approved by the University Health Network Animal Care Committee (Animal Use Protocol 4152), in accordance with relevant provincial and federal statutes. Animals were housed in a dedicated facility and cared for by dedicated veterinary staff.

VX2 tumor inoculation was successful in all 15 rabbits. Review of CT images consistently demonstrated a solitary mass in the right lower lobe (Fig. 1a) that progressively increased in size over time (Fig. 1b). There were no obvious changes in lymph node appearance in the initial 2 week period after inoculation (Fig. 1c); however, increasing size became apparent at later time points (Fig. 1d). Longer-term inoculation increased the likelihood of detecting nodal metastases using IHC (Table 1). All metastases detected at ≤ 7 days inoculation were classified as isolated tumor cells (ITCs; i.e., AE1/AE3⁺ deposits < 0.2 mm in size); the one rabbit with ITCs in the left (contralateral) paratracheal node also had ITCs in the right (ipsilateral) paratracheal node. From 8 days onward, all metastatic deposits were classified pathologically as micrometastases (0.2–2 mm) or macrometastases (> 2 mm). Representative images demonstrating negative lymph nodes, ITCs, micrometastases, and macrometastases are shown in Fig. 2.

There was no statistically significant difference in lymph node volume and the presence of VX2 metastases for both the right (p = 0.41) and left (p = 0.07) paratracheal nodes, although positive nodes tended to be larger (Fig. 3a, b). Note that the left paratracheal node was not successfully identified in two rabbits from the 8–14-day cohort and therefore these rabbits were excluded from analysis of left (contralateral) metastases. By comparison, the volume of the primary tumor was associated with detection of VX2 metastases for both the right (p = 0.001) and left (p = 0.005) paratracheal nodes (Fig. 3c, d). Accurate primary tumor volume was not available for 1 rabbit due to development of a bronchopleural fistula from the tumor with associated pneumothorax, requiring sacrifice as a humane endpoint (Fig. 1e). This rabbit’s primary tumor data was therefore excluded from primary tumor volume analysis. However, lymph node measurements and tissue from both paratracheal nodes were still able to be obtained and included in lymph node volume analysis. For rabbits with right (ipsilateral) paratracheal nodal metastases, primary tumors were ≥ 960 mm³ (equivalent to a 12 mm diameter sphere). For left (contralateral) paratracheal nodal metastases, the primary tumor volume cut-off was less clear given outliers in both the node-positive and node-negative groups. Excluding these outliers, contralateral metastases were detected starting at approximately 5700 mm³ (equivalent to a 22 mm diameter sphere). This is a conservative estimate, however, and the outliers would support that contralateral metastases develop with smaller primary tumors.

Despite the differences unique to transbronchial rabbit VX2 lung tumor models (i.e., lung injection, use of ECM media), it appears these models can generate nodal metastases relatively early after inoculation. We found that primary tumor size predicted the likelihood of nodal metastases; however, we recognize this may be a confounder for time from inoculation. Further investigation on whether tumor size has an independent effect on nodal metastasis is needed. By comparison, we were somewhat surprised that lymph node volume was not associated with the likelihood of metastases. This may be related to initial reactive lymphadenopathy from the bronchoscopic procedure, which enlarged early “negative” nodes and thus reduced our ability to detect statistically significant differences. Although metastases at later time points demonstrated large macrometastases, this subgroup was too small to generate significant results. An argument could be made to extend observation beyond 21 days to increase the number of animals with large nodal metastases, but in practice this would prove difficult. The longest surviving rabbit, at 24 days post-inoculation, demonstrated increasingly rapid interval tumor growth between scans and already had complete replacement of the right lower lobe with tumor by the time of autopsy. Such animals are under significant physiological stress that makes them poor models for investigating new technologies and techniques, given their questionable ability to tolerate additional procedures. Nonetheless, we expect that had we access to a larger cohort of long-inoculated rabbits, a clearer correlation between lymph node size and likelihood of nodal metastasis would have been detected. On the opposite extreme, we have not definitively identified the earliest time point at which nodal metastases develop, as even in the earliest cohort (≤ 7 days) we could detect lymph node metastases. Nonetheless, the reduced yield of nodal metastases in this early cohort would suggest that lymph node metastases likely first begin appearing around 5–7 days post-inoculation.

Relating these results to previous reports on VX2 nodal metastases is difficult given the heterogeneity of prior work. The timing of nodal metastases can vary by primary inoculation site. Xu et al. reported that VX2 endometrial cancer models only developed histologically-proven metastases at 21 days [2]. By comparison, there are reports of auricular cancer models developing nodal metastases within 7 days [20]. Local tissue environments, including oxygen tension, vascularity, and tissue compliance, may contribute to these differences. Focusing on only lung VX2 models highlights further differences. In three studies that employed VX2 lung tumor models and reported on nodal metastases, one study injected a cell suspension without ECM under CT guidance, and one performed transbronchial injection of a cell suspension with ECM under X-ray guidance but with a much larger inoculum than used in this study, and one implanted a 1-mm³ piece of minced VX2 tumor directly into the lung under CT guidance with no reported cell count [12‐14]. Those studies that most clearly identified the time of nodal metastasis relied on autopsy after rabbits expired from disseminated disease without intervention, ranging from 26 to 40 days post-inoculation [12, 13]. The timing of nodal metastasis detection in imaged and/or treated rabbits was less clear, but in general seem to have been detected at 4 weeks or more after inoculation [12, 14]. We have shown here that rabbits develop nodal metastases well prior to these time points. Our data suggests the use of ECM did not impair the ability to form early nodal metastases, even before the 2-week period in which ECM is usually resorbed [13]. This may be related to our use of ECM suspension during intramuscular propagation, which could select out cell populations that more easily breakdown ECM. That slight modifications to VX2 propagation may alter nodal metastasis patterns has been previously shown by Kim et al., who found that altering their VX2 intramuscular passaging method (by processing the lymph node rather than the primary tumor) improved their nodal metastasis rate over time [19]. A final key differentiating factor of our study was the routine use of IHC for all lymph nodes to evaluate for metastases, which improved detection of small tumor deposits that have a higher likelihood to be otherwise missed on routine H&E alone (particularly ITCs).

There are some caveats to this study. The timing of the CT scans was not consistent for all rabbits, resulting in insufficient longitudinal data to generate accurate growth curves. These growth curves may have been an additional predictor of nodal metastases, including the ability to account for any baseline variability in nodal size. Contralateral paratracheal nodal metastases must be understood in the context of rabbit mediastinal lymphatic anatomy, which differs from humans. Subcarinal lymph nodes are inconsistently present in NZW rabbits, which presumably contribute to a propensity for bilateral mediastinal involvement [18]. The bilateral ITCs seen in one rabbit at ≤ 7 days inoculation may be a reflection of this phenomenon. We also recognize that our overall sample size is small; we have attempted to compensate for this through use of non-parametric statistical tests. Finally, our pathological evaluation used slides from the region of maximal diameter, rather than from the entirety of the lymph node. It is therefore possible our results underestimate the timing of nodal metastasis development.

We have demonstrated that rabbit VX2 lung tumor models can reliably generate nodal metastases. Importantly, this occurs relatively early after inoculation compared to previous experience with VX2 tumor models. Transbronchial injection of VX2 tumor cells in rabbits may represent a valuable model for the investigation of novel therapeutic strategies intended for both early-stage and locally advanced lung cancer, depending on the timing after inoculation.